CI

At a glance

ClinicalIndex Comparison Record
Phase 2Completed· 5 enrolled
Drug / intervention
Tc 99m tilmanoceptdrug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT02201420
NCT02201420Phase 2Completed
CompareCT.gov

Evaluation of Technetium Tc 99m Tilmanocept Localization, Retention, and Distribution in Primary Cutaneous Kaposi's Sarcoma (KS) and Lymphatic Drainage From KS Lesions by SPECT/CT Imaging.

Navidea Biopharmaceuticals·interventional·Posted Jul 28, 2014·Updated Sep 27, 2016

In Brief

A Phase 2 clinical trial evaluating Tc 99m tilmanocept for Kaposi's Sarcoma. Completed, enrolled 5 participants across 1 site.

Detailed Summary

The purpose of this study (NAV3-12) is to determine the dissemination and localization of Tc 99m tilmanocept by SPECT and SPECT/CT imaging in subjects with confirmed cutaneous KS. This is a single center, open-label, within-subject study.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsKaposi's Sarcoma
CountriesUnited States
Collaborators--

Timeline

Phase 2CompletedFinished
201520162017201820192020202120222023202420252026
First PostedJul 28, 2014
Enrollment StartSep 1, 2014
Primary CompletionMar 1, 2015
Study CompletionOct 1, 2015
TodayJul 2, 2026
Enrollment to primary: 6 monthsPosted 11.9 years ago

Interventions

Tc 99m tilmanoceptdrug